1 2 3 4 5 6 7
далее 25 (4 SuppI. 9): 35-43 7. Rinaldi M, Crino L, Scagliotti GV, et al. A three-week schedule of gemcitabine-cisplatin in advanced non-small-cell lung cancer with two different cisplatin dose levels: a phase II randomized trial.AnnOncol.2000; 11:1295-300 8. L?pez-Vivanco G., Rubio I., Ma?? J. et all. Biweekly schedule of cisplatin with prolonged infusion of gemcitabine in advanced non small cell lung cancer (NSCLC). J Clin Oncol v.24 N 18S Part I of II, June 2006 [17093] 9. Albain K.S., Jablons D., Werner-Wasik M., et all. Stage III Non-Small Cell Lung Cancer: Tailored Therapies for a Complex Disease. ASCO, 2006. Education Book. pp. 453-461 10.ZatloukalP, PetruzelkaL,ZemanovaM,etal. Gemcitabine plus cisplatin versus gemcitabine plus carboplatrin in stage Illb and IV non-small cell lung cancer: a phase III randomized trial. Lung Cancer 2003; 41: 321-31 11. Masters G. A., Nickolov A., Hahn E., et all. Gemcitabine (GEM) and carboplatin (CARB) in elderly patients with advanced non-small cell lung cancer (NSCLC): Subset analysis of a randomized phase II trial J.CIin.Oncol. Vol 23, № 16S Part I and II. June 1, 2005 [7236] 12. Kosmidis P. A., Kalofonos C., Syrigos K., et all. Paclitaxel and gemcitabine vs carboplatin and gemcitabine. A multicenter, phase III randomized trial in patients with advanced inoperable non-small cell lung cancer (NSCLC) J.CIin.Oncol. Vol 23, № 16S Part I and II. June 1, 2005 [7000] 13. Casal Rubio J., V?zquez Estevez S., et all. Gemcitabine/Docetaxel (GD) vs Gemcitabine/Cisplatin (GC) in stage IIIB/IV advanced non-small cell lung cancer (NSCLC). J Clin Oncol v.24 N 18S Part I of II, June 2006 [17017] 14. Zhang Y., Zhang L, Li N., et all. Gemcitabine plus cisplatin versus gemcitabine plus vinorelbine in the treatment of advanced non-small cell lung cancer (NSCLC) J.CIin.OncjI. Vol 23, № 16S Part I and II. June 1, 2005 [7329] 15. Ramnath N., Sommers E., Robinson L., et all/ Phase II study of neoadjuvant chemotherapy with gemcitabine and vinorelbine in resectable non-small-cell lung cancer (NSCLC) J.CIin.Oncol. Vol 23, № 16S Part I and II. June 1, 2005 [7277] 16. NCCN. Clinical Practice Guidelines in Oncology.v.2.2006 17. Hanna N.. Shepherd F.A., Fosella F.V. et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J.CIin.Oncol. 2004, 22: 1589-1597 18. Demarinis F., Paul S., Hanna N., etall. Survival update for the phase III study of pemetrexed ys docetaxel in non-small cell lung cancer (NSCLC). J Clin Oncol v.24 N 18S Part I of II, June 2006 [7133] 19. Clarke S, Millward M, Findlay M et al. Activity of the multi-targeted antifolate MTA (LY231514) in advanced non-small cell lung cancer (NSCLC). Ann Oncol. 1998;9:86 20. Rusthoven J, Eisenhauer E, Butts С et al. Multitargeted antifolate, LY231514, as first-line chemotherapy for patients with advanced non-small-cell lung cancer: a phase II study. J. Clin. Oncol. 1999;17:1194-1199 21. Shepherd F.A., далее ...